KR20140066124A - 점도가 감소된 제제 - Google Patents

점도가 감소된 제제 Download PDF

Info

Publication number
KR20140066124A
KR20140066124A KR1020137029164A KR20137029164A KR20140066124A KR 20140066124 A KR20140066124 A KR 20140066124A KR 1020137029164 A KR1020137029164 A KR 1020137029164A KR 20137029164 A KR20137029164 A KR 20137029164A KR 20140066124 A KR20140066124 A KR 20140066124A
Authority
KR
South Korea
Prior art keywords
formulation
viscosity
ser
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137029164A
Other languages
English (en)
Korean (ko)
Inventor
미르나 에이. 몬크
맨 이 왕
카이 장
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20140066124A publication Critical patent/KR20140066124A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020137029164A 2011-04-07 2012-04-06 점도가 감소된 제제 Withdrawn KR20140066124A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473123P 2011-04-07 2011-04-07
US61/473,123 2011-04-07
PCT/US2012/032464 WO2012141978A2 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (1)

Publication Number Publication Date
KR20140066124A true KR20140066124A (ko) 2014-05-30

Family

ID=47009919

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137029164A Withdrawn KR20140066124A (ko) 2011-04-07 2012-04-06 점도가 감소된 제제

Country Status (12)

Country Link
US (1) US20140044727A1 (cg-RX-API-DMAC7.html)
EP (1) EP2694708A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014510152A (cg-RX-API-DMAC7.html)
KR (1) KR20140066124A (cg-RX-API-DMAC7.html)
CN (1) CN103582724A (cg-RX-API-DMAC7.html)
AU (1) AU2012243126A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013025845A2 (cg-RX-API-DMAC7.html)
CA (1) CA2832560A1 (cg-RX-API-DMAC7.html)
EA (1) EA201391489A1 (cg-RX-API-DMAC7.html)
IL (1) IL228626A0 (cg-RX-API-DMAC7.html)
SG (1) SG193964A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012141978A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180082971A (ko) * 2017-01-11 2018-07-19 (주)셀트리온 안정한 액체 제제
KR20190140464A (ko) * 2017-04-28 2019-12-19 암젠 인크 인간 항-rankl 항체 제형 및 이의 이용 방법

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3295957T (pt) * 2010-01-15 2019-11-12 Kirin Amgen Inc Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase
EP2694100A4 (en) * 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS HAVING REDUCED VISCOSITY
WO2013190047A1 (en) * 2012-06-21 2013-12-27 Ucb Pharma S.A. Pharmaceutical formulation
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
PH12018500379B1 (en) 2015-08-24 2022-11-23 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CN105733250B (zh) * 2016-05-04 2017-12-26 山东省药学科学院 一种交联聚谷氨酸悬浮液及其制备方法与应用
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN110913887A (zh) * 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
CA3141857A1 (en) * 2019-04-23 2020-10-29 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1324776B2 (en) * 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20050164929A1 (en) * 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
ATE352316T1 (de) * 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
US20050053666A1 (en) * 2002-12-31 2005-03-10 Stelios Tzannis Antibody-containing particles and compositions
PL1942939T5 (pl) * 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
ES2750254T3 (es) * 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2515941B1 (en) * 2009-12-21 2019-11-13 F.Hoffmann-La Roche Ag Pharmaceutical formulation of bevacizumab
CA2794864A1 (en) * 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180082971A (ko) * 2017-01-11 2018-07-19 (주)셀트리온 안정한 액체 제제
KR20190140464A (ko) * 2017-04-28 2019-12-19 암젠 인크 인간 항-rankl 항체 제형 및 이의 이용 방법

Also Published As

Publication number Publication date
EP2694708A2 (en) 2014-02-12
WO2012141978A2 (en) 2012-10-18
CN103582724A (zh) 2014-02-12
EP2694708A4 (en) 2014-10-01
BR112013025845A2 (pt) 2018-09-04
EA201391489A1 (ru) 2014-02-28
WO2012141978A3 (en) 2012-12-27
AU2012243126A1 (en) 2013-10-17
JP2014510152A (ja) 2014-04-24
CA2832560A1 (en) 2012-10-18
US20140044727A1 (en) 2014-02-13
IL228626A0 (en) 2013-12-31
SG193964A1 (en) 2013-11-29

Similar Documents

Publication Publication Date Title
KR20140066124A (ko) 점도가 감소된 제제
KR20140018966A (ko) 점도가 감소된 제제
JP6541581B2 (ja) 低濃度抗体製剤
ES2791690T3 (es) Formulaciones liofilizadas
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
JP2022500386A (ja) Ｃｓｆ−１ｒ抗体製剤
CN106659785A (zh) 包含gm‑csf中和化合物的液体制剂
KR20230009897A (ko) 항-IL-23p19 항체를 포함하는 제제, 이의 제조방법 및 용도
JPWO2008029908A1 (ja) 抗体を含有する安定な凍結乾燥医薬製剤
WO2014141149A1 (en) Formulations with reduced viscosity
CN119095618B (zh) 用于治疗巨噬细胞活化综合征的组合物和方法
JP2024539265A (ja) 製剤
CN119095618A (zh) 用于治疗巨噬细胞活化综合征的组合物和方法
AU2022369042A1 (en) Formulations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid